- Home
- HLP vs ICU Comparison
HLP vs ICU Comparison
Compare HLP & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- ICU
- Stock Information
- Founded
- HLP 2021
- ICU 2018
- Country
- HLP China
- ICU United States
- Employees
- HLP N/A
- ICU N/A
- Industry
- HLP Industrial Machinery/Components
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- HLP Industrials
- ICU Health Care
- Exchange
- HLP Nasdaq
- ICU Nasdaq
- Market Cap
- HLP 23.0M
- ICU 22.1M
- IPO Year
- HLP 2023
- ICU N/A
- Fundamental
- Price
- HLP $1.21
- ICU $4.03
- Analyst Decision
- HLP
- ICU
- Analyst Count
- HLP 0
- ICU 0
- Target Price
- HLP N/A
- ICU N/A
- AVG Volume (30 Days)
- HLP 41.7K
- ICU 24.8K
- Earning Date
- HLP 11-24-2024
- ICU 11-12-2024
- Dividend Yield
- HLP N/A
- ICU N/A
- EPS Growth
- HLP N/A
- ICU N/A
- EPS
- HLP N/A
- ICU N/A
- Revenue
- HLP $14,045,084.00
- ICU N/A
- Revenue This Year
- HLP N/A
- ICU N/A
- Revenue Next Year
- HLP N/A
- ICU $344.44
- P/E Ratio
- HLP N/A
- ICU N/A
- Revenue Growth
- HLP N/A
- ICU N/A
- 52 Week Low
- HLP $0.72
- ICU $3.25
- 52 Week High
- HLP $5.54
- ICU $42.93
- Technical
- Relative Strength Index (RSI)
- HLP 31.47
- ICU 38.70
- Support Level
- HLP $1.14
- ICU $3.82
- Resistance Level
- HLP $1.40
- ICU $4.18
- Average True Range (ATR)
- HLP 0.14
- ICU 0.24
- MACD
- HLP -0.02
- ICU 0.06
- Stochastic Oscillator
- HLP 16.54
- ICU 32.50
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll formed steel profile manufacturer in China. It customizes and manufactures cold roll formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture and transportation.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.